Please login to the form below

Not currently logged in

Amylin and Takeda discontinue obesity drug

Amylin Pharmaceuticals and Takeda Pharmaceutical Company discontinue pramlintide/metreleptin combined obesity treatment following a commercial reassessment

Amylin Pharmaceuticals and Takeda Pharmaceutical Company announced their decision to discontinue the development of pramlintide/metreleptin, a combination therapy for the treatment of obesity. 

This decision was reached after a “commercial reassessment” of the programme. This assessment took into account various factors including a revised development plan and the evolving dynamics within the obesity therapeutic area.

The drug comprised of pramlintide, an analogue of the natural hormone amylin, and metreleptin, an analogue of the natural hormone leptin. At the time of discontinuation, the drug was in its phase II stage, where it was an injection formula taken twice a day. 

Despite the discontinuation, Amylin and Takeda will continue to work together, and will continue to investigate the antibody-related laboratory finding with metreleptin treatment. Neither of the companies are expecting to revise the latest financial guide for their respective 2011 year. 

5th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...